MedPath

Use of Virtual Reality to Reduce Morphine Consumption in Adolescents Undergoing Scoliosis Surgery

Not Applicable
Completed
Conditions
Scoliosis
Interventions
Device: Virtual Reality (VR) technique
Drug: Analgesic protocol
Registration Number
NCT04892940
Lead Sponsor
University Hospital, Toulouse
Brief Summary

The objective is to evaluate the effect of the association of virtual reality sessions with usual management on the cumulative consumption of morphine equivalent post-operatively in adolescents aged 13 to 18 years who have undergone scoliosis surgery.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
101
Inclusion Criteria
  • Patient between 13 and 18 years old, i.e. the age to use a virtual reality helmet according to the manufacturer's recommendations.
  • Patient with an indication for idiopathic scoliosis surgery.
  • Free, informed and signed consent by patients (or parents/parental guardians) and the investigator (no later than the day of inclusion and prior to any review required by the research)
Exclusion Criteria
  • Patient undergoing surgery for neurological scoliosis.
  • Impossibility to use the VR helmet (blindness, eye infection, helmet wound, epilepsy, psychiatric or cognitive disorder incompatible with VR).
  • History of adverse effects while wearing an VR helmet (nausea, vomiting, headache, visual disturbances)
  • Patient with a contraindication to the use of morphinics
  • Patient whose both parents benefit from a legal protection measure (guardianship, curatorship, safeguard of justice)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Virtual Reality groupVirtual Reality (VR) techniqueAdolescents aged 13 to 18 years who have undergone scoliosis surgery
Virtual Reality groupAnalgesic protocolAdolescents aged 13 to 18 years who have undergone scoliosis surgery
Control groupAnalgesic protocolAdolescents aged 13 to 18 years who have undergone scoliosis surgery
Primary Outcome Measures
NameTimeMethod
Cumulative amount of morphine (mg) consumed for each participant.From day 1 to day 3 postoperatively
Secondary Outcome Measures
NameTimeMethod
Cost-effectiveness ratioFrom day 1 to day 6 postoperatively

Calculated by taking into account the costs collected from the point of view of health insurance and the number of patients having avoided side effects at 6 days

Maximum level of pain assessed on a scale of 1 to 10From day 1 to day 6 postoperatively

The patient will assess his pain on a scale ranging from 1 to 10, 1 being a very low pain to 10 very strong pain.

Treatment prescribed to combat the side effects of morphineBetween day 1 and day 3 postoperatively

Nature of treatment

daily dose of morphineFrom day 1 to day 6 postoperatively

daily dose of morphine equivalent in milligrams (mg) then related to the weight in milligrams per kilogram (mg/kg)

Morphine-related side effectsBetween day 1 and day 3 postoperatively

Number and nature of morphine-related side effects

Dose of treatment prescribed to combat the side effects of morphineBetween day 1 and day 3 postoperatively

Dose in mg

Duration of treatment prescribed to combat the side effects of morphineBetween day 1 and day 3 postoperatively

Number of days

Number of drug treatments as well as the purchase price of RV from a hospital perspectiveFrom day 1 to day 6 postoperatively
Intensity of pain assessed on a scale of 1 to 10.At day 3 postoperatively

The patient will assess his pain on a scale ranging from 1 to 10, 1 being a very low pain to 10 very strong pain.

Side effects related to the use of the virtual realityFrom day 1 to day 3 postoperatively

Number of side effects

Trial Locations

Locations (1)

CHU Toulouse

🇫🇷

Toulouse, France

© Copyright 2025. All Rights Reserved by MedPath